Investigational Drug Information for TK-112690
✉ Email this page to a colleague
What is the development status for investigational drug TK-112690?
TK-112690 is an investigational drug.
There have been 3 clinical trials for TK-112690.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2019.
The most common disease conditions in clinical trials are Mucositis and [disabled in preview]. The leading clinical trial sponsors are Tosk, Inc., SIRO Clinpharm Private Limited, and SIRO Clinpharm Pvt. Ltd.
Summary for TK-112690
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 633 |
| WIPO Patent Applications | 332 |
| Japanese Patent Applications | 122 |
| Clinical Trial Progress | Phase 2 (2019-05-15) |
| Vendors | 0 |
Recent Clinical Trials for TK-112690
| Title | Sponsor | Phase |
|---|---|---|
| Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690 | SIRO Clinpharm Private Limited | Phase 2 |
| Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690 | Tosk, Inc. | Phase 2 |
| Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690 | SIRO Clinpharm Pvt. Ltd. | Phase 2 |
Clinical Trial Summary for TK-112690
Top disease conditions for TK-112690
Top clinical trial sponsors for TK-112690
US Patents for TK-112690
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
